Lung cancer (LC) is one of the most common malignancies worldwide, with rising incidence and mortality rates in recent years. According to the World Health Organization (WHO), there were approximately 18.1 million new cancer cases and 9.6 million cancer-related deaths worldwide in 2018. Of these, 2.09 million (11.5%) of all new cancers were LC, while 1.76 million (18.3%) of all cancer-related deaths were from LC [28]. Approximately 934,700 new cases of LC were reported in China in 2016, representing an incidence of 73.48 per 100,000 individuals. Additionally, there were approximately 440,500 deaths, resulting in a death rate of 56.82 per 100,000 individuals [29]. LC is now the leading cause of cancer-related death in men worldwide, and the second leading cause in women [30]. The histopathological subtypes of LC are classified as small cell LC and non-small cell LC (NSCLC). The latter accounts for the majority (85%) of cases and includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma [31]. Early-stage LC may show mild or even no typical clinical manifestations. Consequently, the majority of patients are diagnosed at an advanced stage, with the presence of lymph node or distant metastases. This adversely affects both the treatment outcomes and prognosis of LC [32]. Therefore, establishing early diagnosis and implementing timely interventions has major significance for disease progression and prognosis. At present, LC diagnosis relies primarily on a combination of clinical manifestations, diagnostic imaging, biochemical tests, and histopathological analysis. The biomarkers carcinoembryonic antigen (CEA), cancer antigen 125 (CA125) and cytokeratin 19 fragment (CYFRA21-1) are widely used in the detection and diagnosis of LC, but are more accurate for the diagnosis of advanced LC rather than early LC [33]. Meanwhile, molecular diagnostics is gradually improving and showing increasingly advantageous features [27]. Among these methods, the molecular expression profile of cancer samples show good potential for cancer classification. However, classical molecular diagnostic tests are limited by the availability of tissue samples and are somewhat hindered in clinical practice by time and space constraints. The development of liquid biopsies has addressed these problems very well. In the subsequent section, we provide a comprehensive review of TEP RNA and cfRNA in the context of LC research.

Li et al. [32] utilized lncRNA microarrays to investigate the potential diagnostic value of TEP RNA in LC. They found that the expression levels of the TEP lncRNAs GTF2H2-1 and RP3-466P17.2 in LC patients were significantly lower than in the healthy population, whereas the levels of TEP lncRNA ST8SIA4-12 was significantly higher (p = 0.0001). Similar differences were observed between individuals with early-stage LC and the normal population. To further investigate the accuracy of TEP RNA for LC diagnosis, the researchers constructed receiver operating characteristic (ROC) curves. TEP lnc-GTF2H2-1, RP3-466P17.2 and ST8SIA4-12 showed good performance as biomarker complexes for the diagnosis of LC, with a combined area under the curve (AUC) of 0.921, sensitivity of 82.6%, and specificity of 87.1%. Additionally, these biomarker complexes showed promising diagnostic potential for early-stage LC, with a combined AUC of 0.895, sensitivity of 93.6%, and specificity of 69.8%. Furthermore, TEP linc-GTF2H2-1 had the ability to distinguish between patients with early- and advanced-stage LC. When combined with other biomarkers such as CEA, CYFRA21-1, and neuron-specific enolase (NSE), the diagnostic performance of TEP linc-GTF2H2-1 for distinguishing between intermediate and advanced stages was significantly enhanced (AUCs of 0.799, 0.806, and 0.790, respectively). The results were significantly better than those of each biomarker alone (AUCs of 0.780, 0.797 and 0.773, respectively). Lastly, the combination of these four biomarkers resulted in a notable improvement in LC diagnosis (AUC of 0.899, sensitivity of 76.6%, and specificity of 85.0%), thus further emphasizing the potential role of TEP RNA in tumor diagnosis and assessment of disease progression. Another study used a similar approach to investigate the levels of Apoptotic Chromatin Condensation Inducer 1 (ACIN1) mRNA in platelets derived from 146 LC patients and 58 healthy individuals [33]. The level of ACIN1 mRNA was found to be significantly higher in platelets from LC patients compared to platelets from healthy controls (p = 0.015). Moreover, ROC curve analysis for LC detection showed a sensitivity of 82.7%, specificity of 44.8%, accuracy of 0.724, and AUC of 0.608. The ACIN1 mRNA level was not significantly correlated with age, sex, type of pathology, or presence of metastasis (p 0.05). Thus, TEP ACIN1 mRNA may be a novel, specific molecular biomarker for LC diagnosis. Another study found that it might be an m-RNA of ITGA2B and SELP that platelets overexpress rather than in their protein form in early stage of LC, then play a role in mRNA form [34]. These were significantly elevated in NSCLC (p 0.001). Furthermore, they could accurately differentiate between NSCLC and controls, with an AUC of 0.922 for ITGA2B mRNA and 0.799 for SELP mRNA in the training cohort, and 0.888 and 0.716 respectively in the validation cohort. Both ITGA2B mRNA and SELP mRNA are therefore potentially useful for NSCLC diagnosis, with ITGA2B being superior. An elevated level of ITGA2B mRNA was also identified as an independent risk factor for poor overall survival (OS) in NSCLC patients. By combining ITGA2B, CEA and clinical staging, a predictive model for OS was constructed that led to substantial improvement in the prognostic assessment of NSCLC. Nilsson et al. [35] conducted a study that compared mRNA from platelets and plasma for the early diagnosis of LC. They evaluated the cancer-induced rearrangement of echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) mRNA. This mRNA exhibited higher diagnostic efficacy in platelets (65% sensitivity and 100% specificity) compared to plasma (21% sensitivity and 100% specificity), suggesting that RNA derived from platelets may be a more reliable biomarker for diagnosing LC. Co-incubation experiments showed that exosomes derived from LC cell lines could transfer tumor-derived, EML4-ALK rearranged RNA into platelets. This result highlights a potential mechanism by which tumor cells can manipulate platelet behavior in the circulation. The researchers continuously monitored the platelet level of EML4-ALK rearranged RNA during the entire course of treatment in LC patients and found that it was altered in response to targeted drug administration. Moreover, alterations in platelet EML4-ALK expression were observed approximately two months before drug resistance-associated changes were detected by conventional imaging methods. This finding could help with earlier identification of LC patients showing drug resistance phenomenon after targeted therapy. The study also revealed a close correlation between EML4-ALK levels in platelets and shorter progression-free survival (PFS) of patients, thus providing clinicians with more precise and timely guidance for clinical decision-making.

Researchers have also focused on the role of cfRNA in the diagnosis and treatment of tumors, with studies showing that both quantitative and qualitative analysis of cfRNA can guide the selection of treatment options and monitor treatment efficacy [36]. Furthermore, cfRNA has broader applications compared to TEP RNA since it encapsulates a range of information, including the transcriptome of cancer cells, mutational data, and epigenetic regulatory information [37]. Hence, further in-depth studies on the application of cfRNA for early diagnosis, prognostic assessment and monitoring treatment response in LC appear warranted.

The miR-21 microRNA has been linked to various cancer types, including NSCLC [38], liver cancer [39], and pancreatic cancer [40]. Significantly higher miR-21 levels were observed in the plasma of NSCLC patients compared to controls (p 0.0001) [38]. ROC analysis yielded an AUC of 0.729 for miR-21, with a sensitivity of 61.04% and specificity of 83.33%. These findings suggest that plasma miR-21 has the potential to serve as a non-invasive biomarker for the detection of NSCLC. Both surgery (p = 0.0002) and chemotherapy (p = 0.0250) led to significant decreases in the level of miR-21, although neither intervention returned the levels to normal. Thus, plasma miR-21 may be valuable for the early diagnosis of LC, as well as for prognosis. Other studies have also reported altered miR-21 levels in other tumor types, including liver and pancreatic cancer (described separately below). Li et al. [41] reported that plasma miR-486 (p = 0.008) and miR-150 (p = 0.0488) levels could distinguish LC patients from healthy individuals. The AUC for miR-486 was 0.926, with a sensitivity of 90.9% and specificity of 81.8%, while the AUC for miR-150 was 0.752, with a sensitivity and specificity of 81.8% each. Subsequent investigations found that miR-486 (plasma vs. tissue p = 0.0027) was diagnostically superior to miR-150 (plasma vs. tissue p = 0.0876). Moreover, the plasma level of miR-486 before and after surgery showed predictive value for the risk of NSCLC recurrence. Another study reported that the levels of several miRNAs were significantly altered in the serum of NSCLC patients [36]. Specifically, miR-15b-5p was substantially upregulated, whereas miR-16-5p, miR-17b-5p, miR-19-3p, miR-20a-5p, and miR-92-3p were significantly downregulated. The authors constructed a combined prediction model utilizing miR-15b-5p, miR-16-5p, and miR-20a-5p. This demonstrated high sensitivity and specificity in both the training set (AUC = 0.93, sensitivity = 86.17%, specificity = 91.38%) and in the validation set (sensitivity = 94.29%, specificity = 94.23%), suggesting that it could be a useful diagnostic approach for LC.

These findings also highlight the potentially important role of serum RNA in the diagnosis and treatment of cancer, particularly for early detection and prognostic evaluation. It has been reported that serum RNA is accurate and sensitive for the detection of LC metastases, even before these are visible on imaging scans [35]. Serum RNA offers several advantages over tissue biopsy, including non-invasiveness and better visualization of tumor heterogeneity, gene alterations, and clonal evolution, as well as providing a comprehensive view of tumor dynamics [42, 43]. In addition, the evaluation of serum RNA, is very convenient for the monitoring of tumor drug resistance and targeted therapy [44]. Moreover, the postoperative management of cancer patients can be optimized by monitoring tumor burden and detecting minimal residual disease [45]. Further research is needed to validate the possible application of serum RNA in cancer, but these biomarkers have recently become an active area of interest for researchers. They should also help in gaining a better understanding of the mechanisms of cancer development, as well as providing new ideas and approaches for cancer treatment and management.

Primary liver cancer is a prevalent malignancy worldwide, ranking sixth in terms of incidence and second in terms of mortality [46]. It therefore presents a significant threat to human life and well-being. There are approximately 782,000 new cases of hepatocellular carcinoma (HCC) per year worldwide, accounting for 75%–85% of all primary liver cancers [47, 48]. The primary techniques utilized for early, non-invasive detection of HCC include serum alpha-fetoprotein (AFP), ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI). Among these methods, serum AFP and US are the most commonly used diagnostic approaches [49]. Nevertheless, they have a high false-negative rate ranging from 10% to 30%. Hence, there is an urgent need to discover novel indicators with high sensitivity and specificity in order to increase the diagnostic accuracy for early-stage HCC and to facilitate early treatment and improve prognosis. Next, we will review the relevant advances of TEP RNA and cfRNA in HCC research in detail.

Numerous studies have reported that miRNA-122, which is specifically expressed in the liver, is a key regulator in liver development and liver diseases. MiRNA-122 is also upregulated in the peripheral circulation of HCC patients. MiRNA-21 is one of the most prevalent miRNAs in the bloodstream and is present at high levels in nearly all types of solid cancers [38, 40]. In light of these findings, researchers have conducted quantitative real-time polymerase chain reaction (qRT-PCR) assays to assess the diagnostic value of TEP miRNA-122 and TEP miRNA-21 in HCC [39]. The levels of both were significantly increased in individuals with liver cancer compared to normal subjects (p 0.05). With appropriate cut-off values, the diagnostic sensitivity of TEP miRNA-122 reached 100.0% with a specificity of 93.3%, while that of TEP miRNA-21 was 80.0% with a specificity of 93.3%. In another study, TEP miR-495-3p and TEP miR-136-5p showed decreased expression levels in HCC patients compared to controls, whereas TEP miR-1293 showed an increased level [50]. The AUC for miR-1293 was 0.78, and for miR-495-3p it was 0.76. These findings suggest that TEP RNA may serve as an auxiliary diagnostic marker for liver cancer, thus complementing the existing biomolecular library utilized for HCC diagnosis. CfRNA has also been investigated in regard to HCC. Okajima et al. [51] found the plasma miR-224 level in HCC patients was significantly different to that of normal controls (p 0.0001). They did this by mining and analyzing the NCBI database, and then validating with qRT-PCR experiments. Their findings were consistent with results obtained in liver cancer tissues (p = 0.0011) and cell lines (p = 0.0150). Moreover, the plasma assay results were consistent with corresponding tissue assay results (p = 0.0005). Results from a large cohort trial showed that plasma miR-224 displayed high accuracy for the diagnosis of HCC (AUC 0.908) and was also feasible for prognostic assessment (p = 0.0058). These findings offer a new and reliable option for the clinical diagnosis of early-stage HCC. Lin et al. [52] conducted a parallel study to determine if serum miR-224 has the same diagnostic value as plasma miR-224 in patients with HCC. Their findings were remarkably consistent with those of Okajima et al. [51] Serum miR-224 is therefore also considered to be a potential non-invasive biomarker for the early diagnosis and prognostic assessment of HCC. However, neither of these two research groups investigated whether there were differences in the miR-224 level between serum and plasma, nor did they determine which source exhibited superior diagnostic efficacy. Another study confirmed that the serum level of miR-224 in HCC patients was positively related to the BCLC (Barcelona Clinic Liver Cancer) stage (p = 0.005) and was reflective of tumor status and liver injury [53]. Moreover, a notable correlation was observed between serum miR-224 and serum AFP. This further highlights the significance of serum miR-224 as an independent factor in the diagnosis and prognostic assessment of HCC patients throughout the entire clinical diagnosis and treatment process. Ratnasari et al. [54] reported that plasma miRNA 29c-3p derived from patients had an inhibitory effect on tumorigenesis and disease progression. This miRNA can regulate various blood parameters, including the neutrophil-to-lymphocyte ratio (NLR), platelet count, cholinesterase (ChE), and albumin. MiRNA 21-5p and miRNA 155-5p were also found to have tumor-promoting effects and to significantly impact neutrophils in blood biochemical indexes. Therefore, the combined application of clinical indicators and RNA in peripheral blood could greatly improve the accuracy of early diagnosis and prognosis in HCC patients. Another study found that serum miR-375 showed a significant negative correlation with the progression of hepatitis B [55]. The level of serum miR-375 was notably lower in patients with cirrhosis and HBV-HCC (HCC associated with hepatitis B virus) compared to the healthy population (p 0.05). In vitro experiments demonstrated that overexpression of miR-375 significantly inhibited the proliferation and migration of HCC cells. Furthermore, the serum level of miR-375 in patients with elevated AFP and CEA was significantly lower than in individuals with normal levels of these protein biomarkers (p 0.05). MiR-375 had an AUC of 0.838, a sensitivity of 73.9%, and a specificity of 93.0% in the overall cohort. In the liver cancer cohort, miR-375 showed a higher AUC (0.768) and sensitivity (93.8%) compared to AFP (AUC: 0.584, sensitivity: 75.0%). These results suggest that serum miR-375 could be a useful biomarker for the detection of HBV-HCC with relatively high accuracy. A recent study found that serum miR-106b had significant discriminatory value for different stages of HCC (p 0.001), with an AUC of 0.885, sensitivity of 90.0%, specificity of 66.7% [49]. Importantly, the serum miR-106b level was not associated with hepatitis, obesity, or long-term alcohol consumption. Together, these findings demonstrate the great potential of TEP RNA and cfRNA in liver cancer diagnosis, while providing new directions for individualized management and treatment of this disease.

Although great progress has been made in understanding the molecular mechanisms of pancreatic cancer (PC) development, it remains one of the deadliest cancer types. In the absence of new diagnostic methods and/or treatments, PC is expected to become the second leading cause of cancer-related deaths by the end of 2023. Surgical resection is the most effective treatment for PC, but the majority of patients (80–85%) are unable to undergo surgery due to the presence of local invasion and/or distant metastases [56]. Hence, there is an urgent need to develop new biomarkers for the early diagnosis and prognostic assessment of PC in order to enhance the clinical management of these patients [57]. Wang et al. [40] selected four plasma miRNAs (miR-21, miR-210, miR-155 and miR-196a) that are overexpressed in PCs in order to assess their effectiveness as biomarkers. Inhibition of miR-21 was previously found to reduce the proliferation, invasion and migration of pancreatic intraepithelial neoplasia (PanIN) cells in a mouse model, and also to delay the progression of PanIN to PC [58]. Vila-Navarro et al. [59] recently identified a set of 14 miRNAs in plasma that were significantly elevated in the plasma of patients with PC or intraductal papillary mucinous neoplasm (IPMN) compared to healthy controls. These (miRNAs) (let7e-5p, let-7f-5p, miR-103a-3p, miR-151a-5p, miR-151b, miR-16-5p, miR-181a-5p, miR192-5p, miR 21-5p, miR-221-3p, miR-23a-3p, miR-320a, miR-33a-3p and miR-93-5p) have been suggested as potential biomarkers for non-invasive diagnostic procedures in PC, with the combination of miR-33a-3p, miR-320a, and Carbohydrate Antigen 19-9 (CA19-9) showing the highest diagnostic accuracy (AUC = 0.948). Moreover, miR-181b-5p and miR-548d-3p were found to be significantly increased in the plasma of PC patients, but a similar upregulation was not observed in precancerous IPMN patients. These two miRNAs were therefore considered to be potential biomarkers for monitoring the malignant transformation of IPMN, although more prospective validation studies are required before their clinical application. Cao et al. [60] reported that a combination of three plasma miRNAs (miR-486-5p, miR-126-3p, and miR-106b-3p) had an AUC of 0.891 for the differentiation of PC from chronic pancreatitis (CP), thereby surpassing the diagnostic accuracy of CA19-9 (AUC = 0.775). Another study found that the diagnostic value of miR-486-5p alone for differentiating PC patients, CP patients and healthy controls was equivalent to that of CA19-9 [61]. Mazza et al. [62] analyzed three miRNAs (miR-1225p, miR-1273g-3p and miR-6126) overexpressed in PC patients. They found that a combination of plasma miR-1273g-3p with CA19-9 levels could more accurately differentiate PC patients from healthy individuals (AUC = 0.940) compared to miR-1273g-3p alone (AUC = 0.703) and CA19-9 (AUC = 0.906). Plasma miR-181b, miR-196a and miR-210 are reported to have similar properties, and since their levels correlate significantly with lymph node metastasis (p = 0.0010, 0.0008, and 0.0013, respectively), clinical stage (p = 0.0048, 0.0319, 0.0027) and vascular invasion (p = 0.0002, 0.0016, 0.0019), they could be used as prognostic markers [63]. Other investigators have reported that miR-99a-5p, miR-200c-3p, and miR-365a-3p could effectively distinguish PC patients with poor prognosis after resection and those with longer survival times [64].

Breast cancer (BC) is one of the most common and deadly cancers in women worldwide. The incidence of BC (30%) has surpassed that of LC (13%) as the most common malignancy in women worldwide [65]. BC is also the leading cause of cancer-related deaths in the female population, with metastasis and recurrence being the main causes of mortality [66]. The cure rate for $>$90% when the tumor remains localized in the breast. However, if the cancer cells spread to distant sites through metastasis, the 5-year survival rate is 30%. The primary treatment approach for advanced BC involves chemotherapy-based combination therapy. However, the effectiveness of first-line chemotherapy is only 30% to 50%, while the efficacy of second-line chemotherapy is even lower [67]. Early screening and diagnosis therefore play a crucial role in improving BC prognosis and subsequently the treatment outcomes.

On the basis of previous findings, researchers have validated changes in the serum miR-155 level of BC patients [68]. This was significantly increased in BC patients (p 0.001) compared to healthy controls and had good accuracy for the diagnosis of BC (AUC = 0.801, sensitivity of 65.0%, specificity of 81.8%). Tumor resection or adjuvant chemotherapy resulted in significantly lower serum miRNA-155 levels (Comparison before and after surgery: p = 0.0010 and patients after chemotherapy versus healthy people: p = 0.5042). Moreover, the levels of commonly used tumor markers such as carbohydrate antigen 15-3 (CA15-3), CEA and tissue peptide-specific antigen (TPS) did not show this trend. Although the study had the usual limitations, it seems clear that serum miR-155 could be a reliable biomarker for the early diagnosis and prognosis of BC. An in-depth study was also carried out on whether circulating lncRNA H19 could be used as a biomarker for BC diagnosis and surveillance [69]. The results showed significantly increased levels of lncRNA H19 in both BC tissues and plasma (p 0.05), with a high concordance between the two. Moreover, elevated levels of lncRNA H19 exhibited better diagnostic accuracy for BC (AUC = 0.81, specificity = 86.7%) compared to the conventional tumor markers CEA (AUC = 0.52, specificity = 50.0%) and CA153 (AUC = 0.66, specificity = 60.0%). When combined, the three markers showed improved diagnostic accuracy, with an AUC of 0.84 and specificity of 96.7%. A significant decrease in plasma lncRNA H19 level was observed in postoperative samples (p = 0.0006), indicating its potential as a biomarker for early screening and prognostic monitoring of BC. The plasma lncRNA H19 levels also correlated with postoperative residual tumor load (p 0.05) and was different in different BC subtypes (HER2+, ER+, and triple-negative). This biomarker could therefore be a potential predictor for the efficacy of neoadjuvant treatment [70]. Shimomura et al. [71] found that a combination of 5 serum miRNAs (miR-1246, miR-1307-3p, miR-4634, miR-6861-5p and miR-6875-5p) could detect BC with 89.7% accuracy, 97.3% sensitivity and 82.9% specificity. Moreover, platelet TPM3 mRNA entered BC cells via microvesicles and enhanced their ability to infiltrate and metastasize. This observation highlights the potential involvement of platelet microvesicles in BC metastasis and offers new insights for the development of therapeutic approaches that target this process [72]. Plasma miRNA levels may also be predictive for the clinicopathological characteristics, chemotherapy efficacy and prognosis of BC patients with recurrent metastatic cancer [67]. The above findings suggest several new blood-based tumor biomarkers for the diagnosis and treatment of BC. However, further extensive validation studies are required before these findings can be applied in the clinical setting.

Nasopharyngeal carcinoma (NPC) is a common malignant tumor of the nasopharynx, with an annual incidence of 15–50 cases per 100,000 individuals in the southern region of China and Southeast Asian countries [73]. Similar to other cancer types, there are numerous challenges in the early diagnosis of NPC. The detection of DNA and antibodies for Epstein Barr virus (EBV) in the peripheral blood are commonly used diagnostic methods, but have limitations in terms of their sensitivity and specificity. Hence, the identification of novel biomarkers is urgently needed to improve the early detection of NPC. Significantly higher expression levels of TEP miR-34c-3p and TEP miR-18a-5p were reported in patients with NPC (p 0.001) [74]. These also showed high accuracy, sensitivity and specificity for NPC diagnosis (TEP miR-34c-3p: AUC = 0.952, sensitivity = 94.44%, specificity = 86.11% and accuracy = 91.11%; TEP miR-18a-5p: AUC = 0.884, sensitivity = 85.19%, specificity = 86.11%, accuracy = 85.55%). The diagnostic value was improved further with a combination of these two biomarkers (AUC = 0.954, sensitivity = 92.59%, specificity = 86.11%, and accuracy = 90.00%), thus offering hope for better diagnosis and treatment of NPC. In another study, a significant decrease in the TEP lncRNA ROR level was observed in NPC patients compared with healthy individuals (p = 0.0019), whereas no significant difference was found in plasma lncRNA ROR (p = 0.064) [75]. Consequently, the diagnostic potential of TEP lncRNA ROR for NPC is better that of plasma lncRNA ROR, aligning with the conclusion of Nilsson et al. [35] and highlighting the superiority of platelets over plasma in liquid biopsy. ROC analysis of TEP lncRNA ROR revealed an AUC of 0.70, a sensitivity of 60%, specificity of 70%, and an accuracy of 63.9%. When combined with EBV DNA, the positive rate increased from 58.3% (EBV DNA alone) to 74%. These findings indicate that TEP lncRNA ROR could be a valuable complement to EBV DNA and serve as a non-invasive biomarker for the diagnosis of NPC.

Ovarian cancer (OC) is the fifth leading cause of cancer death in women and faces the same challenges of early diagnosis and poor prognosis [76]. Serum miRNAs have been found to correlate with OC diagnosis and may provide a more accurate and reliable method of early diagnosis for the benefit of patients. Among them, miR-200c and miR-141 were effective at distinguishing OC patients from healthy controls (p 0.001), while also correlating with different subtypes and stages of OC (p 0.001). MiR200c (AUC, sensitivity and specificity of 0.79, 72% and 70%, respectively) was superior to miR-141 (AUC, sensitivity and specificity of 0.75, 69% and 72%, respectively) for the diagnosis of OC and thus has great potential as a diagnostic marker. Moreover, the miR-200c level was reported to be prognostic for the survival of OC patients [77].

The high incidence of colorectal cancer (CRC) in developing countries and its poor prognosis [78, 79] have led to an increased focus on the identification of non-invasive biomarkers for this disease. LncRNAs are non-protein-coding RNA molecules of $\ge$200 nucleotides in length [80] that play important roles in various subcellular structure [81]. A recent study [82] found that circulating lncRNAs hold great promise for the diagnosis and prognosis of CRC. The levels of lncRNA ATB (p 0.001) and lncRNA CCAT1 (p = 0.024) were significantly increased in the plasma of CRC patients compared to healthy controls while OCC-1 was not significantly different (p = 0.24) [83]. Further analysis showed that lncRNA ATB had greater discriminatory ability than lncRNA CCAT1 (AUC of 0.78 vs. 0.64). In addition, TEP mRNA TIMP1 expression level showed good performance for the differential diagnosis of CRC (AUC = 0.958) [84]. Xu et al. [85] confirmed the potential diagnostic value of TEP RNA profiles for distinguishing early CRC from non-cancerous disease. In addition, recent studies have shown [86] that platelets activate the C5a/C5aR1 axis through the PSGL-1/JNK/STAT1 signaling pathway in tumor-associated macrophages (TAMs), thereby promoting the development of colorectal cancer. The study provides new insights into the function of platelets in regulating the tumor microenvironment, and targeting intratumoral platelets may be a therapeutic strategy for colorectal cancer patients. Together, these findings suggest a new approach for the early diagnosis and treatment of CRC.

Multiple myeloma (MM) is an incurable malignant hematologic cancer characterized by the clonal growth of plasma cells. The traditional diagnostic method for MM is bone marrow aspiration, but the invasiveness of this procedure and its inability to identify MM heterogeneity are major clinical shortcomings. Although the correlation between TEPs and MM has not been studied in detail, a low mean platelet volume was associated with poor prognosis in MM patients and could therefore be a potential marker of progression and prognosis [87, 88]. The analysis of TEPs in liquid biopsies, may also provide a new method for the diagnosis of MM [89]. Another study recently found that liquid biopsies based on TEP RNA could help in the diagnosis of sarcoma [90].